Rocket Pharmaceuticals (RCKT) Competitors $2.88 +0.29 (+11.20%) Closing price 04:00 PM EasternExtended Trading$2.88 0.00 (-0.17%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock RCKT vs. CRMD, NAGE, WVE, AUPH, ELVN, ABCL, PAHC, VERV, COLL, and NTLAShould you be buying Rocket Pharmaceuticals stock or one of its competitors? The main competitors of Rocket Pharmaceuticals include CorMedix (CRMD), Niagen Bioscience (NAGE), WAVE Life Sciences (WVE), Aurinia Pharmaceuticals (AUPH), Enliven Therapeutics (ELVN), AbCellera Biologics (ABCL), Phibro Animal Health (PAHC), Verve Therapeutics (VERV), Collegium Pharmaceutical (COLL), and Intellia Therapeutics (NTLA). These companies are all part of the "pharmaceutical products" industry. Rocket Pharmaceuticals vs. Its Competitors CorMedix Niagen Bioscience WAVE Life Sciences Aurinia Pharmaceuticals Enliven Therapeutics AbCellera Biologics Phibro Animal Health Verve Therapeutics Collegium Pharmaceutical Intellia Therapeutics Rocket Pharmaceuticals (NASDAQ:RCKT) and CorMedix (NASDAQ:CRMD) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, profitability, dividends, earnings, analyst recommendations, valuation and risk. Do insiders & institutionals believe in RCKT or CRMD? 98.4% of Rocket Pharmaceuticals shares are owned by institutional investors. Comparatively, 34.2% of CorMedix shares are owned by institutional investors. 24.8% of Rocket Pharmaceuticals shares are owned by company insiders. Comparatively, 5.3% of CorMedix shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Does the media favor RCKT or CRMD? In the previous week, Rocket Pharmaceuticals had 23 more articles in the media than CorMedix. MarketBeat recorded 51 mentions for Rocket Pharmaceuticals and 28 mentions for CorMedix. CorMedix's average media sentiment score of 0.52 beat Rocket Pharmaceuticals' score of 0.03 indicating that CorMedix is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rocket Pharmaceuticals 5 Very Positive mention(s) 2 Positive mention(s) 39 Neutral mention(s) 1 Negative mention(s) 4 Very Negative mention(s) Neutral CorMedix 7 Very Positive mention(s) 3 Positive mention(s) 11 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer RCKT or CRMD? Rocket Pharmaceuticals presently has a consensus price target of $18.60, indicating a potential upside of 545.83%. CorMedix has a consensus price target of $17.14, indicating a potential upside of 47.91%. Given Rocket Pharmaceuticals' higher possible upside, equities research analysts clearly believe Rocket Pharmaceuticals is more favorable than CorMedix.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rocket Pharmaceuticals 1 Sell rating(s) 8 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.41CorMedix 0 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.88 Which has stronger earnings & valuation, RCKT or CRMD? CorMedix has higher revenue and earnings than Rocket Pharmaceuticals. Rocket Pharmaceuticals is trading at a lower price-to-earnings ratio than CorMedix, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRocket PharmaceuticalsN/AN/A-$258.75M-$2.63-1.10CorMedix$43.47M18.08-$17.93M$0.2252.68 Which has more volatility & risk, RCKT or CRMD? Rocket Pharmaceuticals has a beta of 0.67, suggesting that its share price is 33% less volatile than the S&P 500. Comparatively, CorMedix has a beta of 1.58, suggesting that its share price is 58% more volatile than the S&P 500. Is RCKT or CRMD more profitable? CorMedix has a net margin of 20.81% compared to Rocket Pharmaceuticals' net margin of 0.00%. CorMedix's return on equity of 22.57% beat Rocket Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Rocket PharmaceuticalsN/A -64.92% -56.13% CorMedix 20.81%22.57%17.02% SummaryCorMedix beats Rocket Pharmaceuticals on 11 of the 16 factors compared between the two stocks. Get Rocket Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RCKT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RCKT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RCKT vs. The Competition Export to ExcelMetricRocket PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$276.58M$2.88B$5.54B$8.87BDividend YieldN/A2.64%5.39%4.10%P/E Ratio-1.1021.3126.1719.90Price / SalesN/A278.47414.67113.66Price / CashN/A41.4736.1356.90Price / Book0.577.518.055.38Net Income-$258.75M-$55.05M$3.15B$248.50M7 Day Performance8.68%2.45%1.85%2.97%1 Month Performance3.97%7.33%4.81%6.02%1 Year Performance-85.44%5.38%34.86%20.39% Rocket Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RCKTRocket Pharmaceuticals4.9137 of 5 stars$2.88+11.2%$18.60+545.8%-87.5%$276.58MN/A-1.10240Trending NewsHigh Trading VolumeCRMDCorMedix2.3588 of 5 stars$16.56+21.7%$15.83-4.4%+175.5%$1.12B$43.47M75.2830Analyst ForecastAnalyst RevisionHigh Trading VolumeNAGENiagen Bioscience1.4985 of 5 stars$13.64+1.5%$19.50+43.0%N/A$1.07B$99.60M80.24120WVEWAVE Life Sciences4.5404 of 5 stars$6.96+5.9%$20.50+194.5%+24.4%$1.07B$108.30M-8.29240Positive NewsAUPHAurinia Pharmaceuticals2.7144 of 5 stars$7.83+0.8%$11.50+46.9%+36.2%$1.06B$235.13M27.96300ELVNEnliven Therapeutics2.4691 of 5 stars$20.29-4.7%$39.60+95.2%-13.4%$995.61MN/A-10.5750Analyst ForecastHigh Trading VolumeABCLAbCellera Biologics2.2401 of 5 stars$3.33-2.3%$8.33+150.3%+25.5%$993.75M$23.11M-5.95500PAHCPhibro Animal Health3.5669 of 5 stars$24.46+2.4%$20.80-15.0%+56.2%$991.36M$1.02B31.361,940VERVVerve Therapeutics3.5023 of 5 stars$11.11+0.5%$14.75+32.8%+126.5%$990.35M$32.33M-5.27110High Trading VolumeCOLLCollegium Pharmaceutical4.0327 of 5 stars$29.88+0.2%$43.75+46.4%-7.1%$960.10M$664.28M24.49210News CoverageNTLAIntellia Therapeutics4.6699 of 5 stars$9.23+0.3%$34.95+278.7%-56.0%$956.04M$57.88M-1.76600 Related Companies and Tools Related Companies CRMD Competitors NAGE Competitors WVE Competitors AUPH Competitors ELVN Competitors ABCL Competitors PAHC Competitors VERV Competitors COLL Competitors NTLA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RCKT) was last updated on 7/2/2025 by MarketBeat.com Staff From Our PartnersElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredTrump's ticking time bombA looming tariff deadline on July 9th could be the spark — but what’s buried inside a recent White House docum...Porter & Company | Sponsored“E.I.”- The biggest prediction of my career?One expert predicts that E.I. could see over 200,000% growth... But you need to move fast...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rocket Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rocket Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RCKT Stock Alerts